John Young - Pfizer Group President of Global Established Pharma Bus.
| PFE Stock | ARS 7,200 90.00 1.27% |
President
Mr. John D. Young is the Group President Pfizer Innovative Health and Angela Hwang of Pfizer Inc, effective January 1, 2018. He was Group President, Global Established Pharma Business from January 2014 until June 2016. President and General Manager, Pfizer Primary Care from June 2012 until December 2013. Primary Care Business Units Regional President for Europe and Canada from 2009 until June 2012. U.K. Country Manager from 2007 until 2009. Director of Johnson Controls International plc. since 2018.
| Age | 58 |
| Tenure | 6 years |
| Phone | 212 733 2323 |
| Web | https://www.pfizer.com |
John Young Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Young against Pfizer stock is an integral part of due diligence when investing in Pfizer. John Young insider activity provides valuable insight into whether Pfizer is net buyers or sellers over its current business cycle. Note, Pfizer insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pfizer'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Young over six months ago Ambarella exotic insider transaction detected | ||
John Young over a year ago Acquisition by John Young of 1017 shares of Exelon subject to Rule 16b-3 | ||
John Young over a year ago Acquisition by John Young of tradable shares of Pfizer subject to Rule 16b-3 | ||
John Young over a year ago Acquisition by John Young of 1029 shares of Exelon subject to Rule 16b-3 |
Pfizer Management Efficiency
The company has return on total asset (ROA) of 0.1332 % which means that it generated a profit of $0.1332 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3687 %, meaning that it generated $0.3687 on every $100 dollars invested by stockholders. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | 0.37 | |||
| Return On Asset | 0.13 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Young, Group President of Global Established Pharma Bus. | ||
| Jennifer Damico, Controller VP | ||
| Christopher CFA, VP Officer | ||
| DVM DVM, Chairman CEO | ||
| Frank DAmelio, CFO and Executive VP of Bus. Operations | ||
| Douglas Lankler, Executive Vice President General Counsel | ||
| Lidia Fonseca, Executive Vice President CTO and Digital Officer | ||
| Angela Hwang, Group President - Pfizer Essential Health | ||
| Mikael MD, Dev Research | ||
| David Denton, Chief VP |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.37 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 52.46 T | |||
| Shares Outstanding | 2.81 B | |||
| Price To Earning | 469.44 X | |||
| Price To Book | 1.60 X | |||
| Price To Sales | 520.74 X | |||
| Revenue | 100.33 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Pfizer Stock
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.